Published in final edited form as:

Cancer Prev Res (Phila). 2014 May ; 7(5): 487–495. doi:10.1158/1940-6207.CAPR-13-0372.

Molecular profiling of premalignant lesions in lung squamous cell carcinomas identifies mechanisms involved in stepwise carcinogenesis

Aik T. Ooi¹, Adam C. Gower¹¹, Kelvin X. Zhang⁴, Jessica L. Vick¹¹, Longsheng Hong³, Brian Nagao³, W. Dean Wallace³, David A. Elashoff^{5,9}, Tonya C. Walser^{7,8}, Steven M. Dubinett^{3,7,8}, Matteo Pellegrini^{6,10}, Marc E. Lenburg¹¹, Avrum Spira^{11,*}, and Brigitte N. Gomperts^{1,2,8,10,*}

¹Mattel Children's Hospital, University of California, Los Angeles, California

²Department of Pulmonary Medicine, University of California, Los Angeles, California

³Department of Pathology and Laboratory Medicine, University of California, Los Angeles, California

⁴Department of Biological Chemistry, Howard Hughes Medical Institute, University of California, Los Angeles, California

⁵Department of Biostatistics, University of California, Los Angeles, California

⁶Department of Molecular, Cell and Developmental Biology, University of California, Los Angeles, California

⁷Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California, Los Angeles, California

⁸The Lung Cancer Research Program of the University of California, Los Angeles, California

⁹Jonsson Comprehensive Cancer Center, University of California, Los Angeles, California

¹⁰Broad Stem Cell Research Center, University of California, Los Angeles, California

¹¹Section of Computational Biomedicine, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA

Abstract

Lung squamous cell carcinoma (SCC) is thought to arise from premalignant lesions in the airway epithelium; therefore studying these lesions is critical for understanding lung carcinogenesis. Previous microarray and sequencing studies designed to discover early biomarkers and therapeutic targets for lung SCC had limited success identifying key driver events in lung carcinogenesis, mostly due to the cellular heterogeneity of patient samples examined and the inter-individual variability associated with difficult to obtain airway premalignant lesions and appropriate normal

Corresponding author: Brigitte N. Gomperts, 10833 Le Conte Ave. A2-410MDCC, Los Angeles CA 90095. 310-206-0772.

bgomperts@mednet.ucla.edu.

*contributed equally as co- senior authors

Disclosure statement: AS is a founder and consultant to Allegro Diagnostics, Inc.

control samples within the same patient. We performed RNA sequencing on laser-microdissected representative cell populations along the SCC pathological continuum of patient-matched normal basal cells, premalignant lesions, and tumor cells. We discovered transcriptomic changes and identified genomic pathways altered with initiation and progression of SCC within individual patients. We used immunofluorescent staining to confirm gene expression changes in premalignant lesions and tumor cells, including increased expression of SLC2A1, CEACAM5, and PTBP3 at the protein level and increased activation of MYC via nuclear translocation. Cytoband enrichment analysis revealed coordinated loss and gain of expression in chromosome 3p and 3q regions, respectively, during carcinogenesis. This is the first gene expression profiling study of airway premalignant lesions with patient-matched SCC tumor samples. Our results provide much needed information about the biology of premalignant lesions and the molecular changes that occur during stepwise carcinogenesis of SCC, and it highlights a novel approach for identifying some of the earliest molecular changes associated with initiation and progression of lung carcinogenesis within individual patients.

Introduction

Lung cancer is the most deadly cancer worldwide, accounting for more deaths than prostate cancer, breast cancer, pancreatic cancer, and colon cancer combined(1). SCC is a common type of non-small cell lung cancer (NSCLC) that accounts for 30% of all lung cancers and is frequently associated with smoking(2). In general, despite current therapeutic strategies of chemotherapy, radiation therapy, and trials with targeted therapies, the overall survival of patients with lung cancer, including SCC, is still very poor with a five-year survival rate of 15.9%(3).

SCC often arises centrally from a large airway, usually a bronchus. Ongoing injury of airway epithelia leads to repair and regeneration that can give rise to a phenotype of squamous metaplasia and subsequently to dysplasia, both of which are histologic features seen in the airways of smokers(4, 5). It is believed that SCC develops through a series of genetic and epigenetic changes that alter the epithelium from squamous metaplasia, then to dysplasia, carcinoma *in situ* and finally to invasive carcinoma(6).

Although there have been studies devoted to discovering the genetic and molecular changes observed in lung cancer, few studies have directly investigated changes associated with squamous metaplasia or dysplasia(7–9). In fact, it is not known with certainty whether premalignant lesions of the airway are the direct progenitors of invasive SCC. This is mainly due to the challenge inherent in following airway premalignant lesions serially over time in the large airways to determine if a particular lesion is destined to develop into SCC. To better understand the process of carcinogenesis leading to SCC, especially those steps involved in the early and precancerous stages, a comprehensive study of the molecular alterations that characterize premalignant lesions is needed along with a direct comparison to the molecular changes found in SCC from that same individual.

Basal cells (BC) of the airway are known to be stem/progenitor cells required for airway epithelial repair(10), and we hypothesize that premalignant lesions arise from aberrant repair in these cells(11). Therefore, we profiled the transcriptome of airway BC, premalignant

lesions and tumors from the same patients to improve our understanding of the stepwise carcinogenesis in SCC and to aid in the identification of new diagnostic and therapeutic approaches for SCC and novel chemopreventive strategies.

Materials and Methods

Case selection and histology review

Resected tissue blocks from SCC cases were reviewed with two pathologists to identify regions of normal airway epithelium, squamous metaplasia or dysplasia, or carcinomas. Patients with fresh frozen or formalin-fixed paraffin-embedded (FFPE) tissue blocks containing all three regions were selected for the study. Immunofluorescent staining of KRT5 was performed to validate the identification of selected lesions. Fresh frozen tissues were used for RNA sequencing, whereas FFPE tissues were used for validation of independent cases with quantitative real-time PCR (qPCR) and immunofluorescent staining.

Laser Capture Microdissection (LCM)

Tissues were sectioned at a 7-micron thickness and mounted on regular uncharged glass slides for patients 1, 2, and 3, and on polyethylene naphthalate (PEN) membrane slides (Leica) for patient 4, followed by H&E staining. LCM was performed using the Arcturus eIIx for patient 1 and 2, Zeiss PALM for patient 3, and Leica LMD7000 for patient 4. A tissue area of 800,000 to 1,200,000 μm^2 was dissected and collected from each lesion.

RNA extraction and sequencing library preparation

RNA was extracted from laser-microdissected cells using the RNeasy Micro Kit (QIAGEN). The cDNA was generated using the Ovation RNA-Seq System (NuGEN) for patients 1 and 2 and the Ovation RNA-Seq V2 System (NuGEN) for patients 3 and 4. For patients 1 and 2, cDNA of ~200 bp was selected by gel purification. For patients 3 and 4, the cDNA was sheared to 140–180 bp using the Covaris focused-ultrasonicator with the following settings: duty cycle 10%; intensity 5; cycles per burst 200; total time 6 minutes. The size range of the sheared cDNA was confirmed by Bioanalyzer analysis prior to library construction using the Encore Library System (NuGEN). The average size of each library was estimated by Bioanalyzer analysis, and the concentration of each was measured on the Qubit fluorometer (Invitrogen).

Sequence analysis

Sequencing libraries from patients 1 and 2 were each sequenced on a single flow cell lane of an Illumina Genome Analyzer IIx, generating 36-base single-end reads, and libraries from patients 3 and 4 were each sequenced on a single flow cell lane of an Illumina HiSeq 2000, generating 50-base single-end reads. All reads were trimmed to 35 bases before alignment. In the case of patient 1, the first base of each read was also trimmed off due to a problem with the first sequencing cycle. Reads that failed Illumina's chastity filter [brightest intensity / (brightest intensity + second brightest intensity) < 0.6 for at least two of the first 25 cycles] were automatically removed during preprocessing. The remaining reads were aligned to the human genome (build hg19) using Bowtie v0.12.7(12), allowing only unique alignments and up to two mismatches per read. Reads aligning to the mitochondrial genome

were removed from further analysis. Gene expression estimates were then computed by measuring the coverage of each of 55,841 Ensembl Gene loci (Ensembl build 69) using the BEDTools software suite(13). The coverage for each Ensembl Gene locus in each sample was then normalized to the size of the locus and the total number of reads mapping uniquely to the nuclear genome to obtain an RPKM(14) value for each gene in each sample. RPKM values were seventh-root-transformed prior to analysis to produce an approximately normal distribution of (nonzero) gene expression values.

Statistical analysis

All models were created using the R environment for statistical computing (version 2.12.0). Linear mixed-effects models were created using the *nlme* R package (version 3.1–97) and negative binomial models were created using the *MASS* R package (version 7.3-7). Student's two-sample *t* test with equal variance (or, in the case of GDS1312, Student's paired *t* test) was used to assess the significance of differential expression of candidate genes in Gene Expression Omnibus (GEO) DataSets. Analysis of GEO DataSets was performed using the preprocessed expression levels generated using default Affymetrix probeset mappings (averaging across multiple probesets to obtain a single expression value for each gene).

Gene Set Enrichment Analysis (GSEA)

Positionally defined (cytoband) Ensembl Gene sets were created using the *biomaRt* R package to extract chromosomal band annotation for Ensembl Gene identifiers using Ensembl version 69. These gene sets were then used to perform pre-ranked GSEA(15) using lists of all Ensembl Genes ranked by the *t* statistics from the linear mixed-effects models, to identify cytobands that were overrepresented among genes coordinately up- or down-regulated in premalignant or tumor cells compared with normal BC. Analysis was performed using GSEA v2.0.8 (build 14) with 1000 permutations, removal of gene sets with > 500 genes, and a random seed of 1234.

Quantitative Real-Time Polymerase Chain Reaction (qPCR)

Amplified cDNA generated during the library preparation for patients 3 and 4 was used for qPCR analysis. In addition, normal BC and premalignant lesions from four independent patients were laser-microdissected from FFPE tissues, and cDNA was generated using the Ovation RNASeq FFPE System. TaqMan Gene Expression Assays (Life Technologies) were used to examine the expression levels of selected candidate genes (*CEACAM5*, *SLC2A1*) in normal BC and premalignant lesions. β 2-microglobulin (*B2M*) was used as an endogenous control. Statistical analysis was performed using the sign test.

Immunofluorescent staining

FFPE tissues were sectioned at a 5-micron thickness and stained as previously described. (11) Antibodies used are: rabbit anti-KRT5, mouse anti-KRT5, mouse anti-PTBP3, rabbit anti-c-myc (Abcam); mouse anti-CEACAM5 (ProMab Biotechnologies Inc); rabbit anti-SLC2A1 (Alpha Diagnostic International); anti-rabbit Cy3, anti-mouse Alexafluor 647, anti-mouse Cy3, anti-rabbit Alexafluor 647 (Jackson ImmunoResearch). Immunostained tissues

were visualized on an AxioCam system (Zeiss), and images were taken using the Axiovision software.

Results

Study population, sample acquisition, and sequence alignment

Fresh frozen tissue blocks were obtained from four individuals with lung SCC (patients 1–4) at the time of tumor resection, and regions of normal BC, premalignant (squamous metaplastic and dysplastic) cells, and tumor cells were successfully captured from sectioned tissues by laser microdissection (Supplementary Fig. S1). The demographic information and clinical characteristics of these patients, as well as a description of the histology of each microdissected premalignant region, are presented in Supplementary Table S1. Sequencing libraries of the expected concentration and cDNA size ranges were generated from RNA isolated from the microdissected cells. All sequenced samples produced reads with mean Phred quality scores above 25, indicating that it was possible to generate sequencing libraries of good quality with our method of isolating RNA from laser-microdissected materials.

A table of the number of reads that aligned uniquely within each sample is shown in Supplementary Table S2. The fraction of reads aligning to the mitochondrial genome varied considerably among samples. In patients 1 and 2, this fraction varied from 7% to 28%, but in patients 3 and 4, mitochondrial reads comprised from 22 to 65% of uniquely aligned reads, with the highest fraction found in the tumor samples from patient 4 (57–65%). Because of this large amount of variability, reads aligning to the mitochondrial genome were discarded from analysis after alignment, and RPKM (reads per kilobase per millions of reads) values were computed relative to the total number of reads aligning uniquely to the nuclear genome.

Identification of genes associated with carcinogenesis

To identify SCC-associated genes whose expression is also associated with progression from normal airway BC to premalignant (metaplastic or dysplastic) lesions, a multi-step procedure was used as outlined in Fig. 1A. First, Ensembl Genes with zero aligned reads in all samples from at least one patient were removed from analysis (to ensure that all patients contributed evidence to each result), leaving 20,817 genes for analysis. This list was then filtered to consider only those genes with substantial evidence of expression (median of greater than 50 uniquely aligned reads across all samples), leaving 7,025 genes for analysis. Using linear mixed-effects models and negative binomial generalized linear models (see Supplementary Methods for details), we then identified 626 early-stage genes (significantly differentially expressed in a similar manner in both premalignant lesions and tumor compared to normal BC), 730 late-stage genes (significantly differentially expressed in a similar manner in tumor compared to both premalignant lesions and normal BC), and 68 "stepwise" genes (significantly differentially expressed in both of the described stages of carcinogenesis) (Fig. 1B, Supplementary Table S3).

Experimental and computational validation of candidate genes

Three genes were selected for further validation: *CEACAM5*, *SLC2A1* and *PTBP3*. These genes, whose expression was upregulated in premalignant lesions and tumor cells compared to normal BC, were chosen because of their potential roles in the biology of lung carcinogenesis. The expression of *CEACAM5* and *SLC2A1* was measured by performing qPCR on remaining material from the sequencing libraries of patients 3 and 4, as well as on laser-microdissected RNA from four additional independent cases (patients 5–8). In each case, the mRNA level of each gene was significantly higher (sign test $p < 0.05$) in the premalignant lesion than in normal BC (Fig. 2A).

Because mRNA and protein levels may not always be well correlated(16–18), immunofluorescent staining was performed in sections of normal epithelium, premalignant lesion, and carcinoma from two independent cases (patients 9 & 10). *CEACAM5* and *SLC2A1* were not detectable in the normal epithelia, but they were highly expressed in cells within both metaplastic lesions and the SCC tumors (Fig. 2B & 2C). *SLC2A1* was expressed throughout the KRT5+ component of the tumor, whereas *CEACAM5* was expressed in some, but not all, KRT5+ tumor cells. *PTBP3* was strongly expressed in premalignant lesions and tumor cells, and although it was strongly expressed in columnar KRT5- cells of normal airway epithelium, its expression was undetectable in normal BC (Supplementary Fig. S2).

To better understand the biological role that these genes may play in the development of lung SCC, the significance of each gene's differential expression was assessed in several Gene Expression Omnibus (GEO) Datasets with respect to experimental parameters relevant to lung SCC carcinogenesis. First, *SLC2A1* and *PTBP3* were confirmed to be significantly upregulated (*SLC2A1*: $p = 0.004$; *PTBP3*: $p = 0.017$) in an independent set of SCC tumors ($n=5$) with respect to paired samples of adjacent normal tissue (GEO DataSet GDS1312) (19); however, the expression of *CEACAM5* was unchanged ($p = 0.64$). Next, a collection of SCC ($n=18$) and adenocarcinoma (ADC) ($n=40$) lung tumors (GDS3627)(20, 21) was interrogated to determine the specificity of the expression of these genes with respect to the SCC tumor type. The expression of *SLC2A1* and *PTBP3* were again strongly increased in SCC tumors compared with ADC tumors (*SLC2A1*: $p = 1.1 \times 10^{-7}$; *PTBP3*: $p = 0.0004$); however, *CEACAM5* was moderately downregulated in SCC relative to ADC ($p = 0.08$). Finally, because premalignant lesions in large central airways are believed to arise from injury caused by cigarette smoking, the expression levels of these genes were examined in a study of bronchoscopic brushings of healthy current ($n=34$), former ($n=18$), and never ($n=23$) smokers (GDS534)(21). In this study, *CEACAM5* and *SLC2A1* were significantly upregulated in brushings from current smokers compared with those from never smokers (*CEACAM5*: $p = 0.0001$; *SLC2A1*: $p = 0.016$), although *PTBP3* was not ($p = 0.66$).

Prediction of chromosomal gains and losses during carcinogenesis

Gene Set Enrichment Analysis (GSEA) performed using positionally defined gene sets (cytobands) revealed that late-stage (but not early-stage) carcinogenesis is associated with a coordinate loss of expression in the p arm of chromosome 3 and an attendant gain of expression in 3q26.33–3q29 (Fig. 3A), which corresponds to previously reported

observations of frequent 3p deletion and 3q amplification in squamous tumors(22, 23). In particular, chromosomal band 3q26.33 has been reported to be consistently amplified in lung SCC(24).

Identification of biological changes in early- and late-stage carcinogenesis

Ingenuity Pathway Analysis (IPA) (Ingenuity Systems) was used to further characterize the changes in biological functions resulting from the differential expression of genes associated with early-stage events, which contribute to the initiation and formation of premalignant lesions, or with late-stage events, which are involved in the progression from premalignant lesions to tumor. This analysis revealed that the early-stage carcinogenesis was characterized uniquely by increased protein ubiquitination and cell cycle progression, whereas the late-stage events were marked primarily by increased transcriptional and translational activity and cellular migration and transformation (Fig. 3B, Supplementary Table S4). In addition, an increase in cell survival and proliferation and a corresponding downregulation of cell death mechanisms was observed throughout both stages of carcinogenesis. IPA was also used to determine whether the genes identified to be differentially expressed either early or late in carcinogenesis are enriched in known targets of various transcription factors. This approach revealed that the set of genes that is differentially expressed early in carcinogenesis and remains dysregulated in tumor cells is enriched in previously reported targets of MYC and TP53 (Fig. 4A, Supplementary Table S5 & S6). As MYC and TP53 are predicted to activate or repress the expression of these targets, respectively, this suggests that MYC activity is significantly induced ($p = 2.41 \times 10^{-5}$, z-score = 3.789) and TP53 activity is potentially repressed ($p = 9.30 \times 10^{-8}$, z-score = -1.034) during early carcinogenesis, and that their activity remains altered throughout tumorigenesis. Importantly, the gene expression levels of *TP53* and *MYC* did not change significantly with respect to the pathological continuum from normal to tumor, suggesting that the predicted changes in their activity are due to post-transcriptional regulation.

To test the hypothesis that MYC activity is induced during early SCC carcinogenesis, immunofluorescent staining of MYC was performed to examine its nuclear and cytoplasmic localization in normal BC, premalignant lesions, and tumor cells (Fig. 4B). MYC staining was exclusive to the nuclei of premalignant lesions and tumor cells. In the histologically normal BC of the airways from patients with lung cancer, however, MYC was localized predominantly in the cytoplasm, although some areas of nuclear staining were also seen. The increased expression of MYC targets in the premalignant lesions and tumor cells, together with a concomitant increase in the nuclear localization of MYC, is strong evidence for a carcinogenesis-associated increase in MYC activity without a significant increase in gene expression.

Discussion

Little is known about the development of premalignant lesions and their progression to SCC because of a lack of appropriate *in vitro* and *in vivo* stepwise models of SCC tumorigenesis. The current practice of profiling whole-tissue biopsies has inherent limitations in the study

of airway premalignancy, as such biopsy samples are highly heterogeneous(7–9) and are therefore potentially subject to confounding cell type-specific effects. The approach described here allows the examination of specific cell populations along the continuum of lung carcinogenesis and the study of relationships between each of these populations. Furthermore, as the premalignant lesions are in close proximity to SCC within the same patients, it is reasonable to expect that alterations in gene expression shared between premalignant and tumor cells reflect molecular changes that occur during carcinogenesis.

We focused specifically on the expression patterns of three genes, *CEACAM5*, *SLC2A1*, and *PTBP3*, that are upregulated in the premalignant lesions (and, in the case of *SLC2A1*, further upregulated in tumor cells). *CEACAM5*, a cell surface glycoprotein that plays a role in cell adhesion and intracellular signaling, has been shown to be important in other epithelial cell cancers, such as colon cancer(25). *SLC2A1* (also known as glucose transporter 1, or GLUT1) is a facilitative glucose transporter associated with hepatocellular cancer and head and neck squamous cell carcinoma(26, 27). *PTBP3* (also known as regulator of differentiation 1, or ROD1) is an RNA-binding protein that regulates pre-mRNA alternative splicing and plays a role in the regulation of cell proliferation and differentiation(28, 29). The protein level expression of each gene was substantially increased in premalignant lesions and tumor cells, although the expression of *CEACAM5* within the tumor cells was more heterogeneous than that of the other genes. Additionally, although *PTBP3* was strongly expressed in normal airway epithelium, its expression was restricted to columnar KRT5- cells.

We also examined the expression of these genes in publicly available microarray datasets related to SCC carcinogenesis. In one such experiment, the genes *SLC2A1* and *PTBP3* were significantly upregulated in lung SCC tumors relative to matched adjacent normal tissue, but unexpectedly, *CEACAM5* was not. However, that study profiled tumor biopsies, which often contain significant stromal contamination; moreover, we observed substantial heterogeneity of *CEACAM5* immunostaining in SCC tumor tissue in this study. The identification of *CEACAM5* as an early-stage marker of squamous lung carcinogenesis in this study may therefore be attributable to the careful laser microdissection of SCC tumor cells from the surrounding stroma.

Because lung SCC is strongly associated with a history of tobacco smoking, we examined the relationship between smoking history and the expression of these genes in a previous study of bronchoscopic brushings. In that study, *CEACAM5* and *SLC2A1* were significantly upregulated in brushings from current smokers compared with those from never smokers. In a subsequent study from the same authors(30), the expression of *CEACAM5* was reported to be irreversibly altered in former smokers for up to several decades after smoking cessation, suggesting that a smoking-associated increase in *CEACAM5* expression in histologically normal airway epithelium may be an early event associated with carcinogenesis in these individuals.

We used GSEA to identify chromosomal regions that were enriched in differentially expressed genes, which suggested that the frequent 3p loss and 3q amplification that are characteristic of SCC (and rare in ADC)(24, 31, 32) are late-stage events in SCC

carcinogenesis. A relevant work by van Boerdonk and colleagues presented a longitudinal study of six patients with squamous metaplastic lesions that showed carcinoma in situ or carcinoma at follow-up bronchoscopy(33). These lesions showed 3p loss and 3q gain when compared to 23 lesions from subjects with no sign of cancer in their follow-up bronchoscopy. The potential discordant result regarding the timing of this genomic amplification of chromosome 3 (early event vs. late event in lung carcinogenesis) may be a result of the different experimental designs of both studies. The van Boerdonk study found chromosomal changes in squamous metaplastic lesions of subjects that had follow-up carcinomas when compared to lesions from subjects with no follow-up carcinomas, but they did not compare the premalignant lesions to normal airway epithelium or SCC from these same individuals to establish the potential stepwise chronology of this molecular event. In our study, we compared premalignant lesions with matched normal basal cells (early-stage) and matched carcinomas (late-stage), all within individual SCC patients. Our data show chromosome 3 abnormalities during late-stage carcinogenesis, suggesting the possibility that the observed 3p loss and 3q gain could have happened at any time point during the progression from squamous metaplasia to carcinomas. We also used IPA to identify biological functions and regulators that were overrepresented among the genes associated with early- or late-stage carcinogenesis. This analysis revealed that early-stage carcinogenesis is marked primarily by increased flux through the cell cycle, but that cellular proliferation continues throughout late-stage carcinogenesis.

Finally, we used IPA to make predictions about the upstream regulators that might be responsible for these changes, and identified the transcription factors TP53 and MYC as likely candidates based on the coordinate differential expression of their target genes. Nuclear expression of MYC in premalignant lesions and tumor cells, suggesting that activation of MYC by nuclear translocation could be an important event contributing to dysregulated cell cycle progression during SCC carcinogenesis. Previous reports have also identified the potential importance of MYC in premalignant lesions of lung carcinoma(31) and breast cancer(34). Further analysis of other datasets is needed to validate the results.

While this study represents a novel approach for identifying driver molecular events associated with squamous cell lung carcinogenesis, there are a number of important limitations to the work. Our model assumes that there is a molecular relationship between the premalignant and tumor cells found within the same patient's airway, although the lesions may develop from disparate clonal populations, thereby limiting the interpretation of those changes as reflecting a stepwise change between lesions. Longitudinal studies of premalignant lesions resampled over time are needed to identify molecular alterations associated with progression or regression within a clonal population of cells. Furthermore, our group and others have previously reported molecular alterations throughout the histologically normal airway of smokers with lung cancer(35). Those molecular events in the histologically normal "field of injury" may reflect some of the earliest events in carcinogenesis and will not be captured directly by our approach. Finally, our study did not evaluate the potential role of stromal cells in initiation and progression of SCC.

In summary, we present a novel approach to identify the molecular alterations that characterize premalignant lesions and carcinogenesis in lung SCC. By isolating and

transcriptome profiling a progenitor cell population within normal airway epithelium, premalignant lesions and SCC from the same individual, we were able to provide unique insight into stepwise molecular alterations that occur during lung carcinogenesis. Our analysis identified coordinate changes in the activity of upstream regulators and the expression of downstream genes within the same patient during early- and late-stage carcinogenesis. Further studies that profile molecular alterations within an individual premalignant lesion followed serially over time (as it progresses or regresses) will provide further resolution to the molecular events associated with lung carcinogenesis. Additional work will also be necessary to determine if any of the genes identified in our study can be used to distinguish premalignant lesions that will progress to cancer from those that will regress. Genes identified and validated in this manner might serve as early biomarkers for SCC detection and targets for SCC chemoprevention.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We would like to thank Gang Liu and Lingqi Luo for performing the RNA-seq of patients 1, 2 and 4, UCLA Broad Stem Cell Research Center High-Throughput Sequencing Core Resource for performing the RNA-seq for patient 3, as well as Frank Schembri for technical assistance in optimizing RNA extraction and Josh Campbell and Nacho Caballero for assistance with negative binomial analysis. Histological services were performed by the UCLA Translational Pathology Core Laboratory (TPCL) and laser microdissection was performed through the TPCL and the Advanced Light Microscopy Core. The statistical analysis for qPCR was performed by Tristan Grogan and supported by NIH/National Center for Advancing Translational Science (NCATS) UCLA CTSI Grant Number UL1TR000124.

Funding sources: This work was supported by Department of Defense (DOD) CTRA LC090615 to SMD, AS, BNG and TCW, Tobacco-Related Disease Research Program (TRDRP) (19FT-0046) to ATO, National Heart, Lung and Blood Institute (NHLBI) R01HL094561-01, CIRM RN2-009-04 to B. Gomperts, the National Cancer Institute (NCI) (#U01-CA152751) to S. Dubinett, A. Spira, B. Gomperts, T. Walser, Department of Defense (DOD) (#W81XWH-10-1-1006) to S. Dubinett, A. Spira, and T. Walser, Department of Veteran Affairs (VA) (#5101BX000359) to S. Dubinett and T. Walser, and TRDRP (#20KT-0055) to T. Walser.

References

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. *CA Cancer J Clin.* 2012; 62:10–29. [PubMed: 22237781]
2. Stat bite: Mortality from lung and bronchus cancer by race/ethnicity, 1998–2002. *J Natl Cancer Inst.* 2006; 98:158. [PubMed: 16449672]
3. Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, et al. Non-small cell lung cancer. *J Natl Compr Canc Netw.* 2012; 10:1236–1271. [PubMed: 23054877]
4. Colby TV, Wistuba II, Gazdar A. Precursors to pulmonary neoplasia. *Adv Anat Pathol.* 1998; 5:205–215. [PubMed: 9859753]
5. Kerr KM. Pulmonary preinvasive neoplasia. *J Clin Pathol.* 2001; 54:257–271. [PubMed: 11304841]
6. Peebles KA, Lee JM, Mao JT, Hazra S, Reckamp KL, Krysan K, et al. Inflammation and lung carcinogenesis: applying findings in prevention and treatment. *Expert Rev Anticancer Ther.* 2007; 7:1405–1421. [PubMed: 17944566]
7. Kettunen E, Anttila S, Seppanen JK, Karjalainen A, Edgren H, Lindstrom I, et al. Differentially expressed genes in nonsmall cell lung cancer: expression profiling of cancer-related genes in squamous cell lung cancer. *Cancer Genet Cytogenet.* 2004; 149:98–106. [PubMed: 15036884]

8. Seo JS, Ju YS, Lee WC, Shin JY, Lee JK, Bleazard T, et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. *Genome Res.* 2012
9. Xi L, Feber A, Gupta V, Wu M, Bergemann AD, Landreneau RJ, et al. Whole genome exon arrays identify differential expression of alternatively spliced, cancer-related genes in lung cancer. *Nucleic Acids Res.* 2008; 36:6535–6547. [PubMed: 18927117]
10. Hong KU, Reynolds SD, Watkins S, Fuchs E, Stripp BR. Basal cells are a multipotent progenitor capable of renewing the bronchial epithelium. *Am J Pathol.* 2004; 164:577–588. [PubMed: 14742263]
11. Ooi AT, Mah V, Nickerson DW, Gilbert JL, Ha VL, Hegab AE, et al. Presence of a putative tumor-initiating progenitor cell population predicts poor prognosis in smokers with non-small cell lung cancer. *Cancer Res.* 2010; 70:6639–6648. [PubMed: 20710044]
12. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol.* 2009; 10:R25. [PubMed: 19261174]
13. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics.* 2010; 26:841–842. [PubMed: 20110278]
14. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. *Nat Methods.* 2008; 5:621–628. [PubMed: 18516045]
15. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A.* 2005; 102:15545–15550. [PubMed: 16199517]
16. Greenbaum D, Colangelo C, Williams K, Gerstein M. Comparing protein abundance and mRNA expression levels on a genomic scale. *Genome Biol.* 2003; 4:117. [PubMed: 12952525]
17. Taniguchi Y, Choi PJ, Li GW, Chen H, Babu M, Hearn J, et al. Quantifying E. coli proteome and transcriptome with single-molecule sensitivity in single cells. *Science.* 2010; 329:533–538. [PubMed: 20671182]
18. Gygi SP, Rochon Y, Franz A, Aebersold R. Correlation between protein and mRNA abundance in yeast. *Mol Cell Biol.* 1999; 19:1720–1730. [PubMed: 10022859]
19. Wachi S, Yoneda K, Wu R. Interactome-transcriptome analysis reveals the high centrality of genes differentially expressed in lung cancer tissues. *Bioinformatics.* 2005; 21:4205–4208. [PubMed: 16188928]
20. Kuner R, Muley T, Meister M, Ruschhaupt M, Buness A, Xu EC, et al. Global gene expression analysis reveals specific patterns of cell junctions in non-small cell lung cancer subtypes. *Lung Cancer.* 2009; 63:32–38. [PubMed: 18486272]
21. Spira A, Beane J, Shah V, Liu G, Schembri F, Yang X, et al. Effects of cigarette smoke on the human airway epithelial cell transcriptome. *Proc Natl Acad Sci U S A.* 2004; 101:10143–10148. [PubMed: 15210990]
22. Brunelli M, Bria E, Nottegar A, Cingarlini S, Simionato F, Calio A, et al. True 3q chromosomal amplification in squamous cell lung carcinoma by FISH and aCGH molecular analysis: impact on targeted drugs. *PLoS One.* 2012; 7:e49689. [PubMed: 23236352]
23. Partridge M, Kiguwa S, Langdon JD. Frequent deletion of chromosome 3p in oral squamous cell carcinoma. *Eur J Cancer B Oral Oncol.* 1994; 30B:248–251. [PubMed: 7950839]
24. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. *Nat Genet.* 2009; 41:1238–1242. [PubMed: 19801978]
25. Pignatelli M, Durbin H, Bodmer WF. Carcinoembryonic antigen functions as an accessory adhesion molecule mediating colon epithelial cell-collagen interactions. *Proc Natl Acad Sci U S A.* 1990; 87:1541–1545. [PubMed: 2304917]
26. Amann T, Maegdefrau U, Hartmann A, Agaimy A, Marienhagen J, Weiss TS, et al. GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. *Am J Pathol.* 2009; 174:1544–1552. [PubMed: 19286567]
27. Heikkinen PT, Nummela M, Jokilehto T, Grenman R, Kahari VM, Jaakkola PM. Hypoxic conversion of SMAD7 function from an inhibitor into a promoter of cell invasion. *Cancer Res.* 2010; 70:5984–5993. [PubMed: 20551054]

28. Sadvakassova G, Dobocan MC, Difalco MR, Congote LF. Regulator of differentiation 1 (ROD1) binds to the amphipathic C-terminal peptide of thrombospondin-4 and is involved in its mitogenic activity. *J Cell Physiol.* 2009; 220:672–679. [PubMed: 19441079]
29. Yamamoto H, Tsukahara K, Kanaoka Y, Jinno S, Okayama H. Isolation of a mammalian homologue of a fission yeast differentiation regulator. *Mol Cell Biol.* 1999; 19:3829–3841. [PubMed: 10207106]
30. Beane J, Sebastiani P, Liu G, Brody JS, Lenburg ME, Spira A. Reversible and permanent effects of tobacco smoke exposure on airway epithelial gene expression. *Genome Biol.* 2007; 8:R201. [PubMed: 17894889]
31. Massion PP, Zou Y, Uner H, Kiatsimkul P, Wolf HJ, Baron AE, et al. Recurrent genomic gains in preinvasive lesions as a biomarker of risk for lung cancer. *PLoS One.* 2009; 4:e5611. [PubMed: 19547694]
32. Massion PP, Kuo WL, Stokoe D, Olshen AB, Treseler PA, Chin K, et al. Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. *Cancer Res.* 2002; 62:3636–3640. [PubMed: 12097266]
33. van Boerdonk RA, Sutedja TG, Snijders PJ, Reinen E, Wilting SM, van de Wiel MA, et al. DNA copy number alterations in endobronchial squamous metaplastic lesions predict lung cancer. *Am J Respir Crit Care Med.* 2011; 184:948–956. [PubMed: 21799074]
34. Ling H, Sylvestre JR, Jolicoeur P. Notch1-induced mammary tumor development is cyclin D1-dependent and correlates with expansion of pre-malignant multipotent duct-limited progenitors. *Oncogene.* 2010; 29:4543–4554. [PubMed: 20562911]
35. Spira A, Beane JE, Shah V, Steiling K, Liu G, Schembri F, et al. Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. *Nat Med.* 2007; 13:361–366. [PubMed: 17334370]

Figure 1. Identification of genes associated with early- or late-stage SCC carcinogenesis

A. Analysis flowchart. Uniquely aligned reads were assigned to 55,841 Ensembl Gene loci (Ensembl build 69). Two statistical models were then applied to identify genes with significant ($p < 0.05$) differential expression between tumor and normal cells, as well as between premalignant and normal cells ("early" genes), between tumor and premalignant cells ("late" genes), or both ("stepwise" genes).

B. Expression heatmap. Root-transformed RPKM values were scaled to a mean of zero and standard deviation of one within each patient; red and blue indicate genes with expression that is higher or lower than the mean within each patient, respectively. Genes are hierarchically clustered within each group (early, stepwise, late).

Figure 2. Experimental validation of *CEACAM5* and *SLC2A1* expression

A. Quantitative realtime PCR. Box plots represent RNA levels of *CEACAM5* and *SLC2A1* in normal BC and premalignant lesions from six patients, showing increased expression of both genes in premalignant lesions compared to normal BC. *B2M* was used as the endogenous control. **B–C.** Immunofluorescent staining of *CEACAM5* and *SLC2A1*. Protein staining shows increased expression of *CEACAM5* and *SLC2A1* in premalignant lesions and SCC compared to BC in the normal epithelium. Top rows: normal airway epithelium; middle rows: premalignant lesions; bottom rows: SCC. Left columns: KRT5, stained in red as marker for BC, premalignant lesions, and tumor cells; middle columns: *SLC2A1* or *CEACAM5*, stained in green; right columns: merged images of left and middle columns. DAPI, stained in blue, as nuclear marker. White scale bars: 50 μ m. Insets show close-up views of the boxed regions.

Figure 3. Identification of coordinately regulated chromosomal regions and pathways

A. Identification of differentially regulated cytobands by GSEA. Positional sets of Ensembl Genes (cytobands) were obtained from Biomart and used to perform pre-ranked GSEA with lists of t statistics (P vs N, T vs P) from the linear mixed-effects models. Dashed lines indicate nominal $p = 0.05$.

B. Identification of dysregulated biological functions by IPA. Selected biological functions ($p < 0.05$ and z -scores ≥ 2 or ≤ -2) predicted to be significantly increased (positive x-axis values) or decreased (negative x-axis values) in early-stage (magenta bars) and late-stage (yellow bars) carcinogenesis.

Figure 4. Identification of MYC as a dysregulated transcription factor in early carcinogenesis

A. Identification of dysregulated transcription factors by IPA. Expression patterns of known downstream targets of TP53 and MYC suggest the inhibition of TP53 and the activation of MYC during early carcinogenesis.

B. Experimental validation of MYC activation in premalignant lesions and SCC.

Immunofluorescent staining shows detection of MYC expression in the nuclei of premalignant lesions and SCC compared to cytoplasmic localization in BC. Top rows: normal airway epithelium; middle rows: premalignant lesion; bottom rows: SCC. Left columns: KRT5, stained in green as marker for BC, premalignant lesion, and tumor cells; middle columns: MYC, stained in red; right columns: merged images of left and middle columns. DAPI, stained in blue, as nuclear marker in all images. White scale bars: 50 μ m. Insets show close-up views of the boxed regions.